Vasoinhibins: Novel inhibitors of ocular angiogenesis

American Journal of Physiology - Endocrinology and Metabolism

Volumn 295, Issue 4, 2008, Pages

  Clapp, Carmen ^a,b   Thebault, Stéphanie ^a   Arnold, Edith ^a   García, Celina ^a   Rivera, José Carlos ^a   De La Escalera, Gonzalo Martínez ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

Author keywords

16K prolactin; Angiogenesis inhibitors; Eye; Prolactin; Vasoproliferative retinopathies

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ENDOSTATIN; EPHRIN A1; PHOSPHOPROTEIN PHOSPHATASE; PIGMENT EPITHELIUM DERIVED FACTOR; UNCLASSIFIED DRUG; VASOINHIBIN; PROLACTIN;

ANGIOGENESIS; APOPTOSIS; BINDING AFFINITY; BLOOD VESSEL PERMEABILITY; DIABETIC RETINOPATHY; DRUG MECHANISM; ELECTRIC POTENTIAL; ENDOTHELIUM CELL; HOSPITAL SERVICE; PREVENTION AND CONTROL; PRIORITY JOURNAL; RETINOPATHY; REVIEW; VASCULARIZATION; VISUAL IMPAIRMENT; ANIMAL; BLOOD FLOW; DRUG EFFECT; EYE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; RETINA DISEASE;

ANGIOGENESIS INHIBITORS; ANIMALS; EYE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROLACTIN; REGIONAL BLOOD FLOW; RETINAL DISEASES;

EID: 56049113735     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90358.2008     Document Type: Review

References (90)

1. Adamis AP, Aiello LP, D'Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis 3: 9-14, 1999.
2. Ando A, Yang A, Mori K, Yamada H, Yamada E, Takahashi K, Saikia J, Kim M, Melia M, Fishman M, Huang P, Campochiaro PA. Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol 191: 116-124, 2002.
3. Aranda J, Rivera JC, Jeziorski MC, Riesgo-Escovar J, Nava G, Lopez-Barrera F, Quiroz-Mercado H, Berger P, Martinez de la Escalera G, Clapp C. Prolactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci 46: 2947-2953, 2005.
4. Atochin DN, Wang A, Liu VW, Critchlow JD, Dantas AP, Looft-Wilson R, Murata T, Salomone S, Shin HK, Ayata C, Moskowitz MA, Michel T, Sessa WC, Huang PL. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest 117: 1961-1967, 2007.
5. Baldocchi RA, Tan L, King DS, Nicoll CS. Mass spectrometric analysis of the fragments produced by cleavage and reduction of rat prolactin: evidence that the cleaving enzyme is cathepsin D. Endocrinology 133: 935-938, 1993.
6. Bentzien F, Struman I, Martini JF, Martial J, Weiner R. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res 61: 7356-7362, 2001.
7. Bloomgarden ZT. Screening for and managing diabetic retinopathy: current approaches. Am J Health Syst Pharm 64: S8-S14, 2007.
8. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 8: 330-334, 2002.
9. Boujon CE, Bestetti GE, Abramo F, Locatelli V, Rossi GL. The reduction of circulating growth hormone and prolactin in streptozocin-induced diabetic male rats is possibly caused by hypothalamic rather than pituitary changes. J Endocrinol 145: 19-26, 1995.
10. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Liou GI, Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 6: 511-524, 2005.
11. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 184: 301-310, 2000.
12. Cerasola GA, Donatelli M, Sinagra D, Russo V, Amico LM, Lodato G. Study of pituitary secretion in relation to retinopathy in patients with juvenile diabetes mellitus. Acta Diabetol Lat 18: 319-328, 1981.
13. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division. Evidence that "physiological hypoxia" is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 36: 1201-1214, 1995.
14. Clapp C. Analysis of the proteolytic cleavage of prolactin by the mammary gland and liver of the rat: characterization of the cleaved and 16K forms. Endocrinology 121: 2055-2064, 1987.
15. Clapp C, Aranda J, Gonzalez C, Jeziorski MC, Martinez de la Escalera G. Vasoinhibins: endogenous regulators of angiogenesis and vascular function. Trends Endocrinol Metab 17: 301-307, 2006.
16. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133: 1292-1299, 1993.
17. Clapp C, Thebault S, Martinez de la Escalera G. Hormones and postpartum cardiomyopathy. Trends Endocrinol Metab 18: 329-330, 2007.
18. Clapp C, Thebault S, Martinez de la Escalera G. Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland. J Mammary Gland Biol Neoplasia 13: 55-67, 2008.
19. Clapp C, Weiner RI. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130: 1380-1386, 1992.
20. Corbacho AM, Martínez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 173: 219-238, 2002.
21. Corbacho AM, Nava G, Eiserich JP, Noris G, Macotela Y, Struman I, Martinez De La Escalera G, Freeman BA, Clapp C. Proteolytic cleavage confers nitric oxide synthase inducing activity upon prolactin. J Biol Chem 275: 13183-13186, 2000.
22. Cosio G, Jeziorski MC, López-Barrera F, De La Escalera GM, Clapp C. Hypoxia inhibits expression of prolactin and secretion of cathepsin-D by the GH4C1 pituitary adenoma cell line. Lab Invest 83: 1627-1636, 2003.
23. 23a. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 5(1/2) years in premature infants with birth weights less than 1251 g. Arch Ophthalmol 120: 595-599, 2002.
24. D'Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 13: 692-704, 1999.
25. D'Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 92: 6374-6378, 1995.
26. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22: 721-748, 2003.
27. Dhanabal M, Sethuraman N. Endogenous angiogenesis inhibitors as therapeutic agents: historical perspective and future direction. Recent Patents Anticancer Drug Discov 1: 223-236, 2006.
28. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol 52, Suppl 1: S3-S19, 2007.
29. Dueñas Z, Rivera JC, Quiróz-Mercado H, Aranda J, Macotela Y, Montes de Oca P, López-Barrera F, Nava G, Guerrero JL, Suarez A, De Regil M, Martínez de la Escalera G, Clapp C. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest Ophthalmol Vis Sci 45: 2049-2055, 2004.
30. Dueñas Z, Torner L, Corbacho AM, Ochoa A, Gutiérrez- Ospina G, López-Barrera F, Barrios FA, Berger P, Martínez de la Escalera G, Clapp C. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Invest Ophthalmol Vis Sci 40: 2498-2505, 1999.
31. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 21: 245-257, 2007.
32. Fleenor D, Petryk A, Driscoll P, Freemark M. Constitutive expression of placental lactogen in pancreatic beta cells: effects on cell morphology, growth, and gene expression. Pediatr Res 47: 136-142, 2000.
33. Folkman J. Angiogenesis. Annu Rev Med 57: 1-18, 2006.
34. Freemark M, Avril I, Fleenor D, Driscoll P, Petro A, Opara E, Kendall W, Oden J, Bridges S, Binart N, Breant B, Kelly PA. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology 143: 1378-1385, 2002.
35. Fujinaka Y, Sipula D, Garcia-Ocana A, Vasavada RC. Characterization of mice doubly transgenic for parathyroid hormone-related protein and murine placental lactogen: a novel role for placental lactogen in pancreatic beta-cell survival. Diabetes 53: 3120-3130, 2004.
36. Fujinaka Y, Takane K, Yamashita H, Vasavada RC. Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-XL upregulation. J Biol Chem 282: 30707-30717, 2007.
37. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98: 2604-2609, 2001.
38. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74: 72-84, 2007.
39. García C, Aranda J, Arnold E, Thébault S, Macotela Y, López-Casillas F, Mendoza V, Quiroz-Mercado H, Hernández-Montiel HL, Lin SH, de la Escalera GM, Clapp C. Vasoinhibins prevent increased retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J Clin Invest 118: 2291-2300, 2008.
40. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 438: 960-966, 2005.
41. Ge G, Fernandez CA, Moses MA, Greenspan DS. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci USA 104: 10010-10015, 2007.
42. Gonzalez C, Corbacho AM, Eiserich JP, Garcia C, Lopez-Barrera F, Morales-Tlalpan V, Barajas-Espinosa A, Diaz-Muñoz M, Rubio R, Lin SH, Martinez de la Escalera G, Clapp C. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145: 5714-5722, 2004.
43. González C, Parra A, Ramírez-Peredo J, García C, Rivera JC, Macotela Y, Aranda J, Lemini M, Arias J, Ibargüengoitia F, de la Escalera GM, Clapp C. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab Invest 87: 1009-1017, 2007.
44. Grosvenor CE, Whitworth NS. Accumulation of prolactin by maternal milk and its transfer to circulation of neonatal rat - a review. Endocrinol Exp 17: 271-282, 1983.
45. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128: 589-600, 2007.
46. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y, Adachi K, Tasaka K, Miyoshi E, Fujiwara N, Taniguchi N, Murata Y. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem 276: 3459-3467, 2001.
47. Hunter PR, Anderson J, Lunn TA, Horrobin DF, Boyns AR, Cole EN. Letter: Diabetic retinopathy and prolactin. Lancet 1: 1237, 1974.
48. Hylander MA, Strobino DM, Pezzullo JC, Dhanireddy R. Association of human milk feedings with a reduction in retinopathy of prematurity among very low birthweight infants. J Perinatol 21: 356-362, 2001.
49. Ikawa H, Irahara M, Matsuzaki T, Saito S, Sano T, Aono T. Impaired induction of prolactin secretion from the anterior pituitary by suckling in streptozotocin-induced diabetic rat. Acta Endocrinol (Copenh) 126: 167-172, 1992.
50. Iranmanesh A, Veldhuis JD, Carlsen EC, Vaccaro VA, Booth RA Jr, Lizarralde G, Asplin CM, Evans WS. Attenuated pulsatile release of prolactin in men with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 71: 73-78, 1990.
51. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 63: 386-393, 2003.
52. Koshida R, Ou J, Matsunaga T, Chilian WM, Oldham KT, Ackerman AW, Pritchard KA Jr. Angiostatin: a negative regulator of endothelial-dependent vasodilation. Circulation 107: 803-806, 2003.
53. Lee H, Struman I, Clapp C, Martial J, Weiner RI. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 139: 3696-3703, 1998.
54. Lee SH, Kunz J, Lin SH, Yu-Lee LY. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res 67: 11045-11053, 2007.
55. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 101: 6605-6610, 2004.
56. Macotela Y, Aguilar MB, Guzmán-Morales J, Rivera JC, Zermeño C, López-Barrera F, Nava G, Lavalle C, Martínez de la Escalera G, Clapp C. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J Cell Sci 119: 1790-1800, 2006.
57. Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol 14: 1536-1549, 2000.
58. Mooradian AD, Morley JE, Billington CJ, Slag MF, Elson MK, Shafer RB. Hyperprolactinaemia in male diabetics. Postgrad Med J 61: 11-14, 1985.
59. Nguyen NQ, Cornet A, Blacher S, Tabruyn SP, Foidart JM, Noel A, Martial JA, Struman I. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol Ther 15: 2094-2100, 2007.
60. Nguyen NQ, Tabruyn SP, Lins L, Lion M, Cornet AM, Lair F, Rentier-Delrue F, Brasseur R, Martial JA, Struman I. Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proc Natl Acad Sci USA 103: 14319- 14324, 2006.
61. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967-3979, 2005.
62. O'Steen WK, Sundberg DK. Patterns of radioactivity in the eyes of rats after injection of iodinated prolactin. Ophthalmic Res 14: 54-62, 1982.
63. Ochoa A, Montes de Oca P, Rivera JC, Dueñas Z, Nava G, de La Escalera GM, Clapp C. Expression of prolactin gene and secretion of prolactin by rat retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 42: 1639-1645, 2001.
64. Ojima T, Takagi H, Suzuma K, Oh H, Suzuma I, Ohashi H, Watanabe D, Suganami E, Murakami T, Kurimoto M, Honda Y, Yoshimura N. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am J Pathol 168: 331-339, 2006.
65. Ostrom KM, Ferris AM. Prolactin concentrations in serum and milk of mothers with and without insulin-dependent diabetes mellitus. Am J Clin Nutr 58: 49-53, 1993.
66. Pan H, Nguyen NQ, Yoshida H, Bentzien F, Shaw LC, Rentier-Delrue F, Martial JA, Weiner R, Struman I, Grant MB. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci 45: 2413-2419, 2004.
67. Piwnica D, Touraine P, Struman I, Tabruyn S, Bolbach G, Clapp C, Martial JA, Kelly PA, Goffin V. Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol 18: 2522-2542, 2004.
68. Pleyer U, Gupta D, Weidle EG, Lisch W, Zierhut M, Thiel HJ. Elevated prolactin levels in human aqueous humor of patients with anterior uveitis. Graefes Arch Clin Exp Ophthalmol 229: 447-451, 1991.
69. Repetto S, Salani B, Maggi D, Cordera R. Insulin and IGF-I phosphorylate eNOS in HUVECs by a caveolin-1 dependent mechanism. Biochem Biophys Res Commun 337: 849-852, 2005.
70. Repka MX, Palmer EA, Tung B. Involution of retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 118: 645-649, 2000.
71. Rivera JC, Aranda J, Riesgo J, Nava G, Thebault S, López-Barrera F, Ramirez M, Martínez de la Escalera G, Clapp C. Expression and cellular localization of prolactin and the prolactin receptor in mammalian retina. Exp Eye Res 86: 314-321, 2008.
72. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 107: 717-725, 2001.
73. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 365: 785-799, 2005.
74. Sima J, Zhang SX, Shao C, Fant J, Ma JX. The effect of angiostatin on vascular leakage and VEGF expression in rat retina. FEBS Lett 564: 19-23, 2004.
75. Simó R, Carrasco E, García-Ramirez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2: 71-98, 2006.
76. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 368: 687-693, 2006.
77. Sorenson RL, Brelje TC. Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res 29: 301-307, 1997.
78. Stone J, Maslim J. Mechanisms of retinal angiogenesis. Prog Retin Eye Res 16: 157-181, 1997.
79. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 96: 1246-1251, 1999.
80. Tabruyn SP, Sabatel C, Nguyen NQ, Verhaeghe C, Castermans K, Malvaux L, Griffioen AW, Martial JA, Struman I. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Mol Endocrinol 21: 1422-1429, 2007.
81. Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, Struman I. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol 17: 1815-1823, 2003.
82. Takahashi K, Saishin Y, Saishin Y, Silva RL, Oshima Y, Oshima S, Melia M, Paszkiet B, Zerby D, Kadan MJ, Liau G, Kaleko M, Connelly S, Luo T, Campochiaro PA. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J 17: 896-898, 2003.
83. Teilum K, Hoch JC, Goffin V, Kinet S, Martial JA, Kragelund BB. Solution structure of human prolactin. J Mol Biol 351: 810-823, 2005.
84. Tilton RG, Chang KC, LeJeune WS, Stephan CC, Brock TA, Williamson JR. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 40: 689-696, 1999.
85. Ueda E, Ozerdem U, Chen YH, Yao M, Huang KT, Sun H, Martins-Green M, Bartolini P, Walker AM. A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr Relat Cancer 13: 95-111, 2006.
86. Ueda EK, Lo HL, Bartolini P, Walker AM. S179D prolactin primarily uses the extrinsic pathway and mitogen-activated protein kinase signaling to induce apoptosis in human endothelial cells. Endocrinology 147: 4627-4637, 2006.
87. Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, Fleming I, Zeiher AM, Kaszkin M, Dimmeler S. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J 16: 706-708, 2002.
88. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 10: 3331-3348, 2004.
89. Zhang SX, Ma JX. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 26: 1-37, 2007.
90. Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol 50: 139-148, 2000.